Co-Diagnostics, Inc. has announced a strategic expansion of its South Asia operations through its joint venture CoSara Diagnostics Pvt. Ltd., formed in partnership with Ambalal Sarabhai Enterprises Limited.

Under the new agreement, CoSara will extend its commercial and distribution footprint beyond India to include Bangladesh, Pakistan, Nepal, and Sri Lanka. This expansion significantly broadens the company’s reach across South Asia, increasing its total addressable market to an estimated USD 13.0 billion, based on internal assessments and third-party data.

The move aligns with CoSara’s plans to commercialize its CoSara PCR Pro point-of-care platform along with the SARAGENE product portfolio across the region, subject to regulatory approvals in each market. As part of the expansion strategy, the company is actively working on establishing robust distribution networks, assessing regulatory pathways, identifying high-priority customer segments, and onboarding regional partners.

Commenting on the development, Mohal Sarabhai, CEO of CoSara, highlighted the strong growth potential of the region, noting that South Asia represents a large and underserved market for molecular diagnostics. He emphasized the increasing demand for accessible, rapid, and reliable testing solutions, particularly for conditions such as tuberculosis, HPV, and upper respiratory infections. He added that the expansion will enable CoSara to build strategic partnerships and enhance access to advanced molecular testing technologies across these markets.

Dwight Egan, CEO of Co-Diagnostics, stated that the expansion reflects the company’s broader global strategy of building regional infrastructure ahead of product commercialization. He noted that by strengthening local manufacturing and distribution capabilities across key geographies—including South Asia, the United States, and the Middle East and North Africa—the company aims to enable scalable deployment of its PCR-based point-of-care solutions and support long-term growth.

To facilitate partner onboarding and market readiness, CoSara plans to host a virtual distributor information session in the second quarter of 2026, followed by an in-person distributor meeting and training program later in the year.

Headquartered in the United States, Co-Diagnostics develops, manufactures, and markets advanced molecular diagnostic technologies. Its platform is based on the detection and analysis of nucleic acid molecules (DNA and RNA), enabling the development of highly accurate diagnostic tests for a wide range of diseases.